JP2023551058A5 - - Google Patents
Info
- Publication number
- JP2023551058A5 JP2023551058A5 JP2023533243A JP2023533243A JP2023551058A5 JP 2023551058 A5 JP2023551058 A5 JP 2023551058A5 JP 2023533243 A JP2023533243 A JP 2023533243A JP 2023533243 A JP2023533243 A JP 2023533243A JP 2023551058 A5 JP2023551058 A5 JP 2023551058A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- formula
- acceptable salt
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/108,938 US20220169606A1 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| US17/108,938 | 2020-12-01 | ||
| GBGB2018955.1A GB202018955D0 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| GB2018955.1 | 2020-12-01 | ||
| US17/208,583 US11773062B2 (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| GB2103981.3 | 2021-03-22 | ||
| GB2103981.3A GB2605144A (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| US17/208,583 | 2021-03-22 | ||
| EPPCT/EP2021/060750 | 2021-04-23 | ||
| PCT/EP2021/060750 WO2021116503A2 (en) | 2020-06-02 | 2021-04-23 | Deuterated compounds |
| PCT/EP2021/062794 WO2021244831A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| US17/320,155 | 2021-05-13 | ||
| GB2106881.2A GB2595776B (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| CA3118556A CA3118556A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| CA3118556 | 2021-05-13 | ||
| EPPCT/EP2021/062794 | 2021-05-13 | ||
| GB2106881.2 | 2021-05-13 | ||
| US17/320,155 US12042564B2 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
| PCT/EP2021/082227 WO2022117359A1 (en) | 2020-12-01 | 2021-11-18 | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023551058A JP2023551058A (ja) | 2023-12-06 |
| JP2023551058A5 true JP2023551058A5 (enExample) | 2024-11-08 |
| JP7834754B2 JP7834754B2 (ja) | 2026-03-24 |
Family
ID=99798988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533243A Active JP7834754B2 (ja) | 2020-12-01 | 2021-11-18 | 重水素化又は部分重水素化ｎ，ｎ－ジメチルトリプタミン化合物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4031529B1 (enExample) |
| JP (1) | JP7834754B2 (enExample) |
| CN (1) | CN116761599B (enExample) |
| AU (1) | AU2021391581B2 (enExample) |
| CA (1) | CA3203020A1 (enExample) |
| IL (1) | IL303288A (enExample) |
| TW (1) | TWI891942B (enExample) |
| WO (1) | WO2022117359A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP2022550463A (ja) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス， インコーポレイテッド | トリプタミン発現を調整する真菌の遺伝子操作 |
| HRP20220797T1 (hr) | 2019-11-07 | 2022-10-14 | Small Pharma Ltd | Spojevi |
| MX2022009527A (es) | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| EP4433049A1 (en) * | 2021-11-18 | 2024-09-25 | Cybin UK Ltd | Injectable and inhalable formulations |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| WO2023130075A2 (en) | 2021-12-31 | 2023-07-06 | Empyrean Neuroscience, Inc. | Genetically modified organisms for producing psychotropic alkaloids |
| MX2024008691A (es) * | 2022-01-14 | 2024-07-19 | Cybin Irl Ltd | Composiciones y metodos de triptamina. |
| US12264131B2 (en) * | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| AU2023361184A1 (en) | 2022-10-13 | 2025-04-24 | Cybin Uk Ltd | Method of administration of a parenteral formulation comprising a psychedelic agent |
| WO2024108195A1 (en) | 2022-11-17 | 2024-05-23 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| AU2024212866A1 (en) | 2023-01-23 | 2025-08-07 | Cybin Uk Ltd | Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent |
| US20240325351A1 (en) | 2023-03-31 | 2024-10-03 | Cybin UK Ltd. | Method of administration |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| TW202617141A (zh) | 2024-07-10 | 2026-05-01 | 英商賽本英國有限公司 | 包含氘化n,n-二甲基色胺之醫藥組合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2337507A1 (en) * | 1998-07-16 | 2000-01-27 | Massachusetts Institute Of Technology | Composition for treatment of stress |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US11723894B2 (en) * | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| MX2022009527A (es) * | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| IL312785B2 (en) * | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| CN116056763B (zh) * | 2020-06-02 | 2024-03-05 | 赛本英国有限公司 | 包含氘代或部分氘代的n,n-二甲基色胺化合物的治疗组合物 |
| WO2021116503A2 (en) * | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| US11000534B1 (en) * | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2021
- 2021-11-18 EP EP21815486.2A patent/EP4031529B1/en active Active
- 2021-11-18 AU AU2021391581A patent/AU2021391581B2/en active Active
- 2021-11-18 CA CA3203020A patent/CA3203020A1/en active Pending
- 2021-11-18 TW TW110143066A patent/TWI891942B/zh active
- 2021-11-18 EP EP23198784.3A patent/EP4275753B1/en active Active
- 2021-11-18 CN CN202180090269.1A patent/CN116761599B/zh active Active
- 2021-11-18 IL IL303288A patent/IL303288A/en unknown
- 2021-11-18 JP JP2023533243A patent/JP7834754B2/ja active Active
- 2021-11-18 WO PCT/EP2021/082227 patent/WO2022117359A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL303288A (en) | N,N-Dimethyltryptamine compounds partially or fully deuterated | |
| TWI765451B (zh) | 作為erk抑制劑的螺環類化合物及其應用 | |
| TWI758999B (zh) | 作為erk抑制劑的噻唑并內醯胺類化合物及其應用 | |
| JP2023531311A5 (enExample) | ||
| JP2022545633A5 (enExample) | ||
| JP3262333B2 (ja) | ５−ｈｔ１ａ拮抗物質としてのピペラジン誘導体 | |
| JP2023527575A5 (enExample) | ||
| ES2922973T1 (es) | Peptidos funcionalizados como agentes antivirales | |
| JP2005511699A5 (enExample) | ||
| WO1993021178A1 (en) | Indole derivatives as 5-ht1-like agonists | |
| JPH0368875B2 (enExample) | ||
| CA2632194A1 (en) | N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | |
| KR920004371A (ko) | 벤조푸란, 벤조티오펜, 인돌 및 인돌리진의 유도체, 그것들의 제조방법 및 그것들을 함유한 조성물 | |
| JP2006522141A5 (enExample) | ||
| JP2006511490A5 (enExample) | ||
| JP2023539113A5 (enExample) | ||
| RU98102128A (ru) | Производные бензо[g]хинолина | |
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов | |
| JP2023542945A5 (enExample) | ||
| JPH0276851A (ja) | ピペリジン誘導体 | |
| TW202328111A (zh) | 內皮素ａ（ｅｔａ）受體拮抗劑化合物、其藥物組合物及其用途 | |
| CN101058535A (zh) | 二(7－羟基－2,3－二氢－1－1h－茚基)醚类及其类似物、合成方法及应用 | |
| EP0233762B1 (en) | Use of aromatic diamines for the treatment of angina pectoris, and diamines therefor | |
| JP2003513075A5 (enExample) | ||
| US5763444A (en) | Antidepressant 1-arylalkyl-4-(alkoxy pyridinyl)-and 4-(alkoxypyrimidinyl) piperazine derivatives |